

Efficient Synthesis of Medium-Sized Cyclic Amines by Means of 2-Nitrobenzenesulfonamide

Toshiyuki Kan, Hideki Kobayashi, Tohru Fukuyama*

Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
Fax +81(3)58028694; E-mail: fukuyama@mol.f.u-tokyo.ac.jp

Received 16 January 2002

Abstract: Construction of medium-sized cyclic amines using 2-nitrobenzenesulfonamides is described. Under either conventional alkylation or Mitsunobu reaction conditions, the cyclization reaction proceeded efficiently to give eight- to ten-membered rings.

Key words: medium-sized cyclic amines, macrocyclization, 2-nitrobenzenesulfonamide, alkylation, Mitsunobu reaction

The construction of medium-sized cyclic amines is an important task in organic synthesis, since such structural units often constitute the frameworks of a variety of medicinally important natural products. Although there are numerous reports on the construction of medium-sized cyclic amines, only a few have implemented direct cyclization with nitrogen nucleophiles.^{1,2} We have recently developed a novel methodology for transformation of primary amines to secondary amines using 2-nitrobenzenesulfonamides as an activating and a protecting group (Ns-strategy).^{3–8} Furthermore, during the course of the total synthesis of lipogrammistin-A, a macrocyclic polyamine, we found that Ns-strategy is effective for the construction of the 18-membered ring (Scheme 1).⁹ We envisioned that this strategy may prove to be a general protocol for the construction of medium-sized cyclic amines. Herein we report novel syntheses of eight- to ten-membered cyclic amines from ω-bromoalcohol by means of 2-nitrobenzenesulfonamide strategy.

As shown in Table 1, the ring closure reactions using 2-nitrobenzenesulfonamide were investigated with non-branched, simple substrates. Coupling between sulfonamide **1** and alcohol **2a–c** was performed under Mitsunobu conditions to give predominantly mono-alkylated products **3a–c**. Preliminary studies on the cyclization with **3a–c**, revealed that some what higher dilution conditions were necessary (0.01 M) to obtain reasonable yields. Thus,

when acetonitrile solution of **3a–c** was slowly added (2 h) via a syringe pump to a mixture of tetrabutylammonium iodide and Cs₂CO₃ in acetonitrile at 60 °C, the cyclization proceeded smoothly to give the desired products **4a–c** in good yields.


Table 1 Cyclization via Conventional Alkylation

Ring size	Alcohol	Alkylation ^a (yield %)	Cyclization ^b (yield %)
8	2a	3a (70)	4a (62)
9	2b	3b (67)	4b (64)
10	2c	3c (74)	4c (66)

^a Alkylation conditions. PPh₃, DEAD, toluene–THF.¹²

^b Cyclization conditions. Cs₂CO₃, CH₃CN, *n*-Bu₄NI, 60 °C.^{12,13}

In order to perform the cyclization under Mitsunobu conditions, the precursors **6a–c** were prepared from *N*-Boc-nitrobenzenesulfonamide **5**¹⁰ (Table 2). Upon treatment of **5** with bromide **2a–c** with K₂CO₃ in DMF, the alkylation reaction proceeded smoothly to give *N*-Boc protected precursors. Subsequent acidic deprotection of the Boc group followed by basic methanolysis of trifluoroacetate with K₂CO₃ in methanol provided the cyclization precursors **6a–c**. Upon treatment of **6a–c** with DEAD and tripe-



Scheme 1

nylphosphine in 0.01 M solution of toluene-THF at room temperature, the desired cyclization reaction proceeded smoothly to afford **4a–c** in good yields.

Table 2 Cyclization via Mitsunobu Reaction

Ring size	Bromide	Alkylation ^a (yield %)	Cyclization ^b (yield %)
8	2a	6a (66)	4a (59)
9	2b	6b (85)	4b (57)
10	2c	6c (62)	4c (62)

^a Alkylation conditions: 1) K_2CO_3 , $n-Bu_4NI$, DMF, 60 °C. 2) TFA, CH_2Cl_2 . 3) K_2CO_3 , MeOH.¹²

^b Cyclization conditions. PPh_3 , DEAD, toluene-THF.¹²

In both protocols for the ring closures, the reactions proceeded successfully without using the branching effect.¹¹ Thus, Ns-strategy proved to be a powerful protocol for the construction of medium-sized rings, overriding the inherent entropic disadvantage of the ring closure. Considering the mildness of the alkylation and the deprotection conditions, Ns-strategy would be compatible with a variety of functional groups. Furthermore, the fact that both alcohols and halides served as starting materials would allow preparation of a wide range of nitrogen heterocycles. Further application of this methodology to the total syntheses of complex natural products is currently under investigation in our laboratories.

References

- For recent syntheses of medium-sized cyclic amines, see: Ring-opening of bicyclic precursors: (a) Donohoe, T. J.; Raouf, A.; Linney, I. D.; Helliwell, M. *Org. Lett.* **2001**, *3*, 861. (b) Fatima, I.; Ramon, G. A.; Juan, C. C. *Org. Lett.* **2001**, *3*, 2957. (c) Cyclization of aminoalkenes: Bergmann, D. J.; Campi, E. M.; Jackson, W. R.; Patti, A. F.; Saylik, D. *Tetrahedron Lett.* **1999**, *40*, 5597. Ring-enlargement of six-membered rings: (d) Moris-Varas, F.; Quian, X.-H.; Wong, C.-H. *J. Am. Chem. Soc.* **1996**, *118*, 7647. Others: (e) Kitano, T.; Shirai, N.; Motoi, M.; Sato, Y. *J. Chem. Soc., Perkin Trans. 1* **1992**, 2851. (f) Shaw, R.; Anderson, M.; Gallagher, T. *Synlett* **1990**, 584. (g) Shaw, R. W.; Gallagher, T. *J. Chem. Soc. Perkin Trans. 1* **1994**, 3549.
- For recent synthesis of medium-sized cyclic amines based on ring-closing metathesis, see: (a) Meyers, A. I.; Downing, S. V.; Weiser, M. J. *J. Org. Chem.* **2001**, *66*, 1413. (b) Heinrich, M. R.; Steglich, W. *Tetrahedron Lett.* **2001**, *42*, 3287. (c) Fujiwara, T.; Kato, Y.; Takeda, T. *Heterocycles* **2000**, *52*, 147. (d) Paquette, L. A.; Leit, S. M. *J. Am. Chem. Soc.* **1999**, *121*, 8126. (e) Visser, M. S.; Heron, N. M.; Didiuk, M. T.; Sagal, J. F.; Hoveyda, A. H. *J. Am. Chem.*

- Soc.* **1996**, *118*, 4291. (f) Miller, S. J.; Kim, S.-H.; Chen, Z.-R.; Grubbs, R. H. *J. Am. Chem. Soc.* **1995**, *117*, 2108.
- For a review on Ns-chemistry, see: Kan, T.; Fukuyama, T. *J. Syn. Org. Chem., Jpn.* **2001**, *59*, 779.
- Fukuyama, T.; Jow, C.-K.; Cheung, M. *Tetrahedron Lett.* **1995**, *36*, 6373.
- Kurosawa, W.; Kan, T.; Fukuyama, T. *Org. Synth.*, in press.
- Fukuyama, T.; Cheung, M.; Jow, C.-K.; Hidai, Y.; Kan, T. *Tetrahedron Lett.* **1997**, *38*, 5831.
- Hidai, Y.; Kan, T.; Fukuyama, T. *Tetrahedron Lett.* **1999**, *40*, 4711.
- Hidai, Y.; Kan, T.; Fukuyama, T. *Chem. Pharm. Bull.* **2000**, *48*, 1570.
- Fujiwara, A.; Kan, T.; Fukuyama, T. *Synlett* **2000**, 1667.
- Fukuyama, T.; Cheung, M.; Kan, T. *Synlett* **1999**, 1301.
- For a review of the substituent effect on the cyclization, see: Jung, M. E. *Synlett* **1999**, 843.
- Experimental procedure for the introduction of Ns-amide and macrocyclization and spectral data for all new compounds are described below.

Representative Experimental Procedures. Synthesis of

3a: To a stirred solution of 2-nitrobenzenesulfonamide (3.20 g, 15.8 mmol), 7-bromo-1-heptanol (**2a**) (1.00 g, 5.13 mmol), and Ph_3P (1.80 g, 8.91 mmol) in toluene (9 mL) and THF (1.2 mL) was added DEAD (4 mL, 8.80 mmol, 40% in toluene) dropwise at 0 °C under argon atmosphere. The solution was stirred at 0 °C for 5 min, then at room temperature for 2.5 h. After removal of the solvent under reduced pressure, the remaining residue was purified by flash chromatography, (9:1 hexane-EtOAc) on a silica gel column, to give **3a** (1.36 g, 70%) as white powder. IR (film, cm^{-1}): 3346, 3096, 2933, 2857, 1539, 1440, 1414, 1360, 1341, 1166, 1125, 1060, 853, 782. ¹H NMR (400 MHz, $CDCl_3$) δ : 1.29 (4 H, m), 1.33 (2 H, m), 1.52 (2 H, m), 1.81 (2 H, m), 3.10 (2 H, q, $J = 6.8$ Hz), 3.37 (2 H, t, $J = 6.8$ Hz), 5.23 (1 H, m), 7.76 (2 H, m), 7.87 (1 H, m), 8.14 (1 H, m). ¹³C NMR (100 MHz, $CDCl_3$) δ : 26.2, 27.8, 28.1, 29.4, 32.5, 33.8, 43.7, 125.3, 131.0, 132.8, 133.5, 133.7, 148.0. FAB-MS: m/z 379 (MH^+); Anal. Calcd. for $C_{13}H_{20}BrN_2O_4S$: C, 41.17; H, 5.05; N, 7.39. Found: C, 41.24; H, 5.04; N, 7.30. Spectral data for **3b** (white powder): IR (film, cm^{-1}): 3346, 3099, 2930, 2856, 1592, 1539, 1440, 1414, 1360, 1342, 1165, 1125, 1061. ¹H NMR (400 MHz, $CDCl_3$) δ : 1.26 (6 H, m), 1.39 (2 H, m), 1.53 (2 H, m), 1.83 (2 H, m), 3.10 (2 H, q, $J = 6.8$ Hz), 3.39 (2 H, t, $J = 6.8$ Hz), 5.23 (1 H, m), 7.75 (2 H, m), 7.87 (1 H, m), 8.15 (1 H, m). ¹³C NMR (100 MHz, $CDCl_3$) δ : 26.4, 28.0, 28.6, 28.9, 29.6, 32.7, 34.0, 43.9, 125.4, 131.2, 132.8, 133.6, 133.8, 148.2. FAB-MS: m/z 393 (MH^+); HRMS (FAB): Found 393.0411 (MH^+), Calcd. 393.0413 ($C_{14}H_{22}BrN_2O_4S$, MH^+). Spectral data for **3c** (white powder). IR (film, cm^{-1}): 3346, 3099, 2930, 2856, 1592, 1539, 1440, 1414, 1360, 1342, 1165, 1125, 1061. ¹H NMR (400 MHz, $CDCl_3$) δ : 1.25 (8 H, m), 1.40 (2 H, m), 1.54 (2 H, m), 1.83 (2 H, t, $J = 4.0$ Hz), 3.10 (2 H, q, $J = 3.4$ Hz), 3.40 (2 H, t, $J = 3.4$ Hz), 5.22 (1 H, m), 7.75 (2 H, m), 7.87 (1 H, m), 8.15 (1 H, m). ¹³C NMR (100 MHz, $CDCl_3$) δ : 26.4, 28.0, 28.5, 28.8, 29.1, 29.5, 32.7, 34.0, 43.8, 125.3, 131.1, 132.7, 133.5, 133.8, 148.1. FAB-MS: m/z 407 (MH^+); Anal. Calcd. for $C_{15}H_{24}BrN_2O_4S$: C, 44.23; H, 5.69; N, 6.88. Found: C, 44.46; H, 5.71; N, 6.64.

Synthesis of 4a: To a stirred solution of Cs_2CO_3 (2.10 g, 6.45 mmol) and TBAI (980 mg, 2.65 mmol) in CH_3CN (3.00 mL) was added *N*-2-nitrobenzenesulfonyl-7-bromo-1-aminoheptane (**3a**) (500 mg, 1.32 mmol) in CH_3CN (24.0 mL) via syringe pump for 2 h at 60 °C, and stirred for additional 2 h at the same temperature. The reaction mixture was poured into water and extracted with EtOAc three times.

The combined organic layer was washed with brine, dried over MgSO_4 , filtered, and evaporated. The residue was purified by flash chromatography (Et_2O) on a silica gel column to give **4a** (245 mg, 62%) as white powder. IR (film, cm^{-1}): 2929, 2857, 1542, 1456, 1373, 1344, 1164, 993. ^1H NMR (400 MHz, CDCl_3) δ : 1.59 (6 H, m), 1.69 (4 H, m), 3.25 (4 H, t, $J = 6.0$ Hz), 7.52 (1 H, m), 7.61 (2 H, m), 7.84 (1 H, m). ^{13}C NMR (100 MHz, CDCl_3) δ : 24.8, 26.5, 27.7, 49.3, 123.9, 130.4, 131.4, 132.5, 133.3, 148.4. FAB-MS: m/z 299 (MH^+); HRMS (FAB): Found 299.0981 (MH^+); Calcd 299.0995 ($\text{C}_{13}\text{H}_{19}\text{N}_2\text{O}_4\text{S}$, MH^+). Anal. Calcd for $\text{C}_{13}\text{H}_{19}\text{N}_2\text{O}_4\text{S}$: C, 52.33; H, 6.08; N, 9.39. Found: C, 52.29; H, 5.99; N, 9.35.

Spectral data for **4b** (white powder): IR (film, cm^{-1}): 2931, 2859, 1725, 1546, 1463, 1373, 1347, 1290, 1161, 1125, 851, 777, 742. ^1H NMR (400 MHz, CDCl_3) δ : 1.32 (8 H, m), 1.57 (4 H, m), 3.25 (4 H, t, $J = 8.0$ Hz), 7.61 (1 H, m), 7.68 (2 H, m), 7.98 (1 H, m). ^{13}C NMR (100 MHz, CDCl_3) δ : 25.9, 27.9, 28.1, 47.8, 124.4, 129.0, 130.9, 131.8, 133.6, 148.4. FAB-MS: m/z 313 (MH^+); Anal. Calcd for $\text{C}_{14}\text{H}_{21}\text{N}_2\text{O}_4\text{S}$: C, 53.83; H, 6.45; N, 8.97. Found: C, 53.87; H, 6.29; N, 8.68. Spectral data for **4c** (white powder): IR (film, cm^{-1}): 2928, 2855, 1542, 1463, 1373, 1346, 1160, 851. ^1H NMR (400 MHz, CDCl_3) δ : 1.32 (10 H, m), 1.57 (4 H, m), 3.29 (4 H, t, $J = 8.0$ Hz), 7.59 (1 H, m), 7.67 (2 H, m), 7.97 (1 H, m). ^{13}C NMR (100 MHz, CDCl_3) δ : 26.2, 27.9, 28.3, 28.5, 48.7, 124.0, 130.6, 131.4, 133.2, 133.3, 148.3. FAB-MS: m/z 327 (MH^+); HRMS (FAB): Found 327.1311 (MH^+); Calcd. 327.1308 ($\text{C}_{15}\text{H}_{23}\text{N}_2\text{O}_4\text{S}$, MH^+); Anal. Calcd for $\text{C}_{15}\text{H}_{23}\text{N}_2\text{O}_4\text{S}$: C, 54.96; H, 6.74; N, 8.30. Found: C, 55.19; H, 6.79; N, 8.58.

Synthesis of 6a: To a stirred solution of *N*-Boc-2-nitrobenzenesulfonamide (**5**) (1.25 g, 4.14 mmol), K_2CO_3 (2.50 g, 18.1 mmol) and tetra-*n*-butylammonium iodide (40 mg, 0.11 mmol) in DMF (7 mL) was added 7-bromo-1-heptanol (770 mg, 3.98 mmol). The solution was stirred at 60 °C for 10 h and then poured into water. The mixture was extracted with EtOAc three times. The combined organic layer was washed with brine, dried over MgSO_4 , filtered, and evaporated. The residue was dissolved in CH_2Cl_2 (1 mL) and TFA (7 mL). After stirring for 1 h, the reaction mixture was concentrated. To the mixture in MeOH was added K_2CO_3 (1.00 g, 7.23 mmol), and stirred for 10 min. The reaction mixture was poured into water and extracted with CH_2Cl_2 three times. The combined organic layer was washed with brine, dried over MgSO_4 , filtered, and evaporated. Recrystallization from ether–hexane afforded **6a** (1.00 g, 60%) as white powder. IR (film, cm^{-1}): 3343, 2933, 2859, 1543, 1413, 1364, 1339, 1165, 1126, 1059, 853, 783, 741. ^1H NMR (400 MHz, CDCl_3) δ : 1.30 (4 H, m), 1.50 (2 H, m),

1.53 (4 H, m), 3.09 (2 H, m), 3.63 (2 H, m), 5.25 (1 H, m), 7.75 (2 H, m), 7.87 (1 H, m), 8.14 (1 H, m). ^{13}C NMR (100 MHz, CDCl_3) δ : 25.5, 26.4, 28.8, 29.5, 32.5, 43.8, 62.9, 125.4, 131.1, 132.8, 133.5, 133.8, 149.8. FAB-MS: m/z 317 (MH^+); HRMS (FAB): Found 317.1180 (MH^+); Calcd 317.1177 ($\text{C}_{13}\text{H}_{21}\text{O}_2\text{N}_5\text{S}$, MH^+).


Spectral data for **6b** (white powder): IR (film, cm^{-1}): 3289, 2931, 2856, 1540, 1418, 1362, 1338, 1163, 1126, 1058. ^1H NMR (400 MHz, CDCl_3) δ : 1.27 (8 H, m), 1.52 (4 H, m), 3.09 (2 H, m), 3.62 (2 H, m), 5.28 (1 H, m), 7.71 (2 H, m), 7.87 (1 H, m), 8.14 (1 H, m). ^{13}C NMR (100 MHz, CDCl_3) δ : 25.5, 26.3, 28.9, 29.1, 29.5, 32.6, 43.8, 62.9, 125.3, 131.1, 132.7, 133.5, 133.8, 148.1. FAB-MS: m/z 331 (MH^+); HRMS (FAB): Found 331.1327 (MH^+); Calcd 331.1329 ($\text{C}_{14}\text{H}_{23}\text{O}_2\text{N}_5\text{S}$, MH^+).

Spectral data for **6c** (white powder): IR (film, cm^{-1}): 3287, 2926, 2853, 1541, 1360, 1333, 1163, 1126, 1062, 854, 780, 728. ^1H NMR (400 MHz, CDCl_3) δ : 1.25 (10 H, m), 1.53 (4 H, m), 3.09 (2 H, q, $J = 6.8$ Hz), 3.63 (2 H, t, $J = 6.8$ Hz), 5.27 (1 H, m), 7.74 (2 H, m), 7.87 (1 H, m), 8.14 (1 H, m). ^{13}C NMR (100 MHz, CDCl_3) δ : 25.6, 26.4, 28.9, 29.2, 29.3, 29.5, 32.7, 43.8, 63.0, 125.3, 131.1, 132.7, 133.5, 133.8, 148.0. FAB-MS: m/z 345 (MH^+); HR MS (FAB): Found 345.1407 (MH^+); Calcd 345.1414 ($\text{C}_{15}\text{H}_{25}\text{O}_2\text{N}_5\text{S}$, MH^+).

Representative Experimental Procedure. Synthesis of **4a** under Mitsunobu Conditions

To a stirred solution of Ph_3P (463 mg, 2.29 mmol) and *N*-(2-nitrobenzenesulfonyl)-7-hydroxy-1-aminoheptane (**6a**) (200 mg, 0.63 mmol) in toluene (48 mL) and THF (16 mL) was added DEAD (1.05 mL, 2.31 mmol, 40% in toluene) drop wise and stirred for 3 h. The reaction mixture was concentrated in vacuo, the residue was purified by flash chromatography (1:4, EtOAc–hexane) on a silica gel column to give **4a** (112 mg, 59%) as white powder.

- (13) Attempted macrocyclization of *N*-*tert*-Butoxycarbonyl-7-iodo-1-aminoheptane (**7**) was failed to the desired reaction as shown in Scheme 2. Treatment of **7** with sodium hydride in DMF at room temperature, the starting material was completely recovered. Upon heating to 60 °C, the dehydroiodination reaction was proceeded to give **8**.



Scheme 2